This article was originally published in The Gray Sheet
Private placement of 3.7 mil. shares nets $26 mil. to fund a two-year capacity expansion project for the firm's r/LS red blood cell filtration system. The expansion is anticipated to result in a greater-than-ten-fold increase in production capability in order to meet demand for leukoreduced blood products. The project will commence in the second quarter and further the American Red Cross goal of 100% leukoreduction by the end of 2000
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.